A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer’s disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 25; no. 1; pp. 162 - 20
• Main Authors: Possemis, Nina, Verhey, Frans, Prickaerts, Jos, Blokland, Arjan, Ramakers, Inez
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.03.2024; BioMed Central; BMC
• Subjects: Activities of daily living; Aging; Alzheimer; Alzheimer's disease; Analysis; Brain research; Chronic obstructive pulmonary disease; Cognition & reasoning; Cognition disorders; Cognitive ability; Cognitive dysfunction; Dementia; Drug dosages; Drug therapy; Executive function; Memory; Mental health; Mild cognitive impairment; Neurobiology; Neuropsychology; Neurosciences; Patient outcomes; Phosphodiesterase 4; Psychiatry; Quality of life; R&D; Research & development; Risk factors; Roflumilast; Signal transduction; Study Protocol; Well being; Netherlands; Phosphodiesterase 4; Drug intervention; Mild cognitive impairment; Memory; Roflumilast; Alzheimer; Randomized controlled trial; Cognitive dysfunction; Dementia

Research into the neurobiological underpinnings of learning and memory has demonstrated the cognitive-enhancing effects associated with diverse classes of phosphodiesterase (PDE) inhibitors. Specific PDE inhibitors have been identified to improve neuronal communication through selective inhibition o...